RXST241220P90000
- 0.00
- 0.000.00%
RxSight Newsroom
Institutional Owners May Consider Drastic Measures as RxSight, Inc.'s (NASDAQ:RXST) Recent US$258m Drop Adds to Long-term Losses
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
RxSight Cut to Equal-Weight From Overweight by Wells Fargo
Wells Fargo Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $42
RxSight Analyst Ratings
UBS Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $52
RxSight's Promising Growth With Light Adjustable Lens: A Buy Recommendation by Danielle Antalffy
Insider Sale: Director at $RXST (RXST) Sells 3,782 Shares
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Jesse Corley Bought 4.4% More Shares In RxSight
RxSight Insider Bought Shares Worth $1,014,570, According to a Recent SEC Filing
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript Summary
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $60
Stifel Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $65
Wells Fargo Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $56
Express News | Rxsight, Inc. : Wells Fargo Raises Target Price to $56 From $54
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $60